GSK Withdraws Application for Leucovorin Calcium After FDA Approval
GlaxoSmithKline asked the U.S. Food and Drug Administration to withdraw its application for leucovorin calcium, a drug that received attention as a potential autism treatment. The request follows the company's earlier submission at the request of health officials and comes after FDA approval last month. GSK said it does not market the product; gene…